Biocon presents key Insights into clinical study that enabled DCGI approval of Itolizumab
A multi-centric, open label, two-arm randomized pivotal clinical trial was conducted in 30 eligible patients at four hospitals…
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.